IGI Logo

Hester Biosciences is currently trading at Rs. 1827.30, up by 23.50 points or 1.30% from its previous closing of Rs. 1803.80 on the BSE.

The scrip opened at Rs. 1844.00 and has touched a high and low of Rs. 1851.10 and Rs. 1781.65 respectively. So far 256 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2851.75 on 11-Apr-2022 and a 52 week low of Rs. 1771.20 on 23-Dec-2022.

Last one week high and low of the scrip stood at Rs. 1999.00 and Rs. 1771.20 respectively. The current market cap of the company is Rs. 1556.76 crore.

The promoters holding in the company stood at 53.73%, while Institutions and Non-Institutions held 0.65% and 45.61% respectively.

Hester Biosciences has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research - National Institute of High Security Animal Diseases (ICAR- NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry. The agreement was signed on December 27, 2022 at the office of Agrinnovate India, New Delhi. Agrinnovate is a government entity that acts as an interface between ICAR and the stakeholders in the agriculture sector, which includes technology transfers for vaccine manufacturing in the veterinary sector.

Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through Hester’s own distribution network, where the demand for this vaccine has already been established. The huge poultry population in India is a key source of livelihood for rural India. Until date, India had no vaccine available for Avian Influenza despite of periodic outbreaks across the country. These factors make this vaccine as having a significant commercial potential.

Hester Biosciences is engaged in the manufacturing of poultry vaccines.